SCHEMBL14478355

SCHEMBL14478355

O=C(O)CN1CCCN(CCc2ccc(N=C=S)cc2)CCNCCCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX12 P18054 1/20 0.46
SIGMAR1 Q99720 3/20 0.45
KCNJ1 P48048 1/20 0.41
KCNH2 Q12809 1/20 0.41
P2RY6 Q15077 1/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
OPRD1 P41143 1/20 0.39
CXCR4 P61073 4/20 0.38
MEN1 O00255 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA2C P18825 1/20 0.38
CCR2 P41597 1/20 0.38
CXCL12 P48061 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14312072 0.97 CYP2D6 (0.46) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14312096 0.93 CYP2D6 (0.49) CYP2D6TP53CYP1A2CYP3A4ALOX12
Tetraxetan SCHEMBL8907977 0.92 CYP2D6 (0.48) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14327153 0.91 CYP2D6 (0.41) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14327160 0.88 CYP2D6 (0.50) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14477647 0.88 CYP2D6 (0.40) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14478356 0.86 SIGMAR1 (0.55) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL8654441 0.86 CYP2D6 (0.54) CYP2D6TP53CYP1A2CYP3A4ALOX12
SCHEMBL14312255 0.86 CXCR4 (0.50) SIGMAR1GRIN1GRIN2AGRIN2BOPRD1
SCHEMBL14477644 0.84 CYP2D6 (0.42) CYP2D6TP53CYP1A2CYP3A4ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130004423-A1 POLYAZAMACROCYCLIC COMPOUND, AND A PRODUCTION METHOD AND A BIOMEDICAL USE THEREFOR KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2013-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130004423-A1 POLYAZAMACROCYCLIC COMPOUND, AND A PRODUCTION METHOD AND A BIOMEDICAL USE THEREFOR SLC39A11, VIP, PBDC1 CYP2D6 4235/4885TP53 2040/4885CYP1A2 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.